These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16932353)

  • 41. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.
    Buddles MR; Donne RL; Richards A; Goodship J; Goodship TH
    Am J Hum Genet; 2000 May; 66(5):1721-2. PubMed ID: 10762557
    [No Abstract]   [Full Text] [Related]  

  • 44. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.
    Timmermans SAMEG; Abdul-Hamid MA; Vanderlocht J; Damoiseaux JGMC; Reutelingsperger CP; van Paassen P;
    Kidney Int; 2017 Jun; 91(6):1420-1425. PubMed ID: 28187980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes.
    Le Quintrec M; Roumenina L; Noris M; Frémeaux-Bacchi V
    Semin Thromb Hemost; 2010 Sep; 36(6):641-52. PubMed ID: 20865641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Posttransplant recurrence of atypical hemolytic uremic syndrome.
    Valoti E; Alberti M; Noris M
    J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report.
    Neidich AB; Neidich EM; Lee A; Nicoletta J; Rohrer RJ; Milner LS; Cooper JT
    Prog Transplant; 2013 Sep; 23(3):213-6. PubMed ID: 23996939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.
    Fakhouri F; Jablonski M; Lepercq J; Blouin J; Benachi A; Hourmant M; Pirson Y; Dürrbach A; Grünfeld JP; Knebelmann B; Frémeaux-Bacchi V
    Blood; 2008 Dec; 112(12):4542-5. PubMed ID: 18658028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting complement C5 in atypical hemolytic uremic syndrome.
    Salant DJ
    J Am Soc Nephrol; 2011 Jan; 22(1):7-9. PubMed ID: 21127140
    [No Abstract]   [Full Text] [Related]  

  • 50. [Atypical hemolytic uremic syndrome and the CFH gene].
    Jiang CR; Ye LY; Yu ZH
    Zhonghua Er Ke Za Zhi; 2008 Dec; 46(12):952-5. PubMed ID: 19134264
    [No Abstract]   [Full Text] [Related]  

  • 51. Alternative complement pathway assessment in patients with atypical HUS.
    Roumenina LT; Loirat C; Dragon-Durey MA; Halbwachs-Mecarelli L; Sautes-Fridman C; Fremeaux-Bacchi V
    J Immunol Methods; 2011 Feb; 365(1-2):8-26. PubMed ID: 21215749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
    Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
    Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.
    Gerber A; Kirchhoff-Moradpour AH; Obieglo S; Brandis M; Kirschfink M; Zipfel PF; Goodship JA; Zimmerhackl LB
    Pediatr Nephrol; 2003 Sep; 18(9):952-5. PubMed ID: 12836093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.
    Saland JM; Emre SH; Shneider BL; Benchimol C; Ames S; Bromberg JS; Remuzzi G; Strain L; Goodship TH
    Am J Transplant; 2006 Aug; 6(8):1948-52. PubMed ID: 16889549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
    Westra D; Volokhina E; van der Heijden E; Vos A; Huigen M; Jansen J; van Kaauwen E; van der Velden T; van de Kar N; van den Heuvel L
    Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Noris M; Remuzzi G
    Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.
    Esparza-Gordillo J; Jorge EG; Garrido CA; Carreras L; López-Trascasa M; Sánchez-Corral P; de Córdoba SR
    Mol Immunol; 2006 Apr; 43(11):1769-75. PubMed ID: 16386793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombomodulin in atypical hemolytic-uremic syndrome.
    Edey MM
    N Engl J Med; 2009 Oct; 361(15):1511; author reply 1511. PubMed ID: 19812413
    [No Abstract]   [Full Text] [Related]  

  • 59. Renal transplantation in patients with atypical haemolytic uraemic syndrome: a tailor made approach is necessary.
    van der Wijk J; Smid WM; Seelen MA; van de Kar NC; Offerman JJ; van Son WJ
    Neth J Med; 2011 Jun; 69(6):279-80. PubMed ID: 21868812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations.
    Kavanagh D; Goodship TH
    Hematology Am Soc Hematol Educ Program; 2011; 2011():15-20. PubMed ID: 22160007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.